{Reference Type}: Journal Article
{Title}: Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.
{Author}: Abdalla AS;Rahman M;Khan SA;
{Journal}: Curr Treat Options Oncol
{Volume}: 25
{Issue}: 7
{Year}: 2024 Jul 12
{Factor}: 5.08
{DOI}: 10.1007/s11864-024-01219-y
{Abstract}: <B>UNASSIGNED: </B>Anaplastic thyroid cancer presents formidable challenges, particularly in cases of recurrence or metastasis. Timely BRAF V600E testing is imperative at diagnosis, initially through immunohistochemistry, followed by comprehensive genomic profiling encompassing genes such as NTRK, RET, ALK, and assessment of tumor mutation burden (TMB). FDA-approved treatment options include dabrafenib and trametinib for patients with BRAF mutations, while those exhibiting high TMB may benefit from pembrolizumab. Further therapeutic decisions hinge upon mutational profile, urgency of response required, airway integrity, and access to targeted therapies There is growing use of immunotherapy for ATC based on published reports of activity, but currently there is no FDA approved agent for ATC. The off-label utilization of "precision medicine" combinations imposes a considerable financial strain, underscoring the necessity for further clinical trials to elucidate promising therapeutic avenues for this orphan disease. There is a pressing need for the development and support of clinical trials investigating genomically driven and immune-based therapies for anaplastic thyroid cancer.